Olfactory Neuroblastoma

• CLINICAL_TRIALS research · 2026-04-14
  Clinical Trial Update: A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma [Phase 2]

  A Phase 2 study of Zanzalintinib for recurrent or metastatic olfactory neuroblastoma is listed as not yet recruiting.

• CLINICAL_TRIALS trial_result · 2026-04-08
  Clinical Trial Update: Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors [Phase 2]

  Phase 2 clinical trial evaluating the IDH2 inhibitor enasidenib (Idhifa) in IDH2-mutated malignant sinonasal and skull base tumors is curren…

• CLINICAL_TRIALS research · 2026-04-08
  Clinical Trial Update: A Natural History Study of Children and Adults With Olfactory Neuroblastoma

  This is a natural history observational study of olfactory neuroblastoma and esthesioneuroblastoma sponsored by the National Cancer Institut…

• CLINICAL_TRIALS research · 2025-10-09
  Clinical Trial Update: Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors [Phase 1, Phase 2]

  A Phase 1/2 clinical trial is evaluating the combination of radiation therapy with a DLL3-targeting bispecific T-cell engager in DLL3-expres…

• CLINICAL_TRIALS trial_result · 2025-08-08
  Clinical Trial Update: Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). [Phase 2]

  A Phase 2 BARON trial evaluating bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma has completed, and the results have been po…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-08-03
  Clinical Trial Update: Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab [Phase 2]

  Phase 2 clinical trial evaluating the efficacy and safety of nivolumab for recurrent/metastatic olfactory neuroblastoma, currently recruitin…

• CLINICAL_TRIALS withdrawal · 2025-01-10
  Clinical Trial Update: A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma [Phase 2]

  A Phase II study of Rivoceranib for recurrent or metastatic olfactory neuroblastoma has been withdrawn from the registry; no results are rep…